<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>cDNA microarray technology coupled with laser microdissection has been used to identify human leukocyte antigen(HLA)-A24-restricted <z:chebi fb="0" ids="53000">epitope</z:chebi> <z:chebi fb="7" ids="16670">peptides</z:chebi> as potential targets for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> vaccination in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>These antigenic <z:chebi fb="7" ids="16670">peptides</z:chebi> were derived from 2 different <z:e sem="disease" ids="C0153594" disease_type="Neoplastic Process" abbrv="">testis cancer</z:e> antigens, ring finger protein 43(RNF43) and translocase of outer <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane 34(TOMM34) </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a clinical trial of vaccines against <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> specific <z:chebi fb="7" ids="16670">peptides</z:chebi>(RNF43 and TOMM34) with tegafur-<z:chebi fb="0" ids="17568">uracil</z:chebi>/Leucovorin( UFT/LV) for the treatment of advanced or <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The vaccinations were well tolerated without any adverse events </plain></SENT>
<SENT sid="4" pm="."><plain>The highest long-term survival was observed in the group showing cytolytic T-lymphocyte (CTL) responses against both RNF43 and TOMM34, followed by the group showing CTL responses against only RNF43 or only TOMM34 </plain></SENT>
<SENT sid="5" pm="."><plain>A new study has been planned in order to obtain more immunological responses, and we have started a clinical trial of vaccines against multiple <z:chebi fb="7" ids="16670">peptides</z:chebi>[RNF43, TOMM34, forkhead box protein M1(FOXM1), maternal embryonic leucine zipper kinase(MELK), holliday junction recognition protein(HJURP), vascular endothelial growth factor receptor (VEGFR)1, and VEGFR2]by using UFT/LV for the treatment of advanced or <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> </plain></SENT>
</text></document>